MyGeneraTM PLATFORM
Gene-specific therapies and their mechanisms
The new category of oligonucleotide gene-specific medicines is characterised by a short chemical sequence of modified DNA that acts on a specific pathological target gene.
Anti-gene
An anti-gene is an oligonucletoide able to inhibit the transcripstion of a target gene ino mRNA
Target gene
(two copies per cell)
Mechanism
The anti-gene oligonucletoide works by forming a stable duplex with the complementary DNA sequence, binding to the open DNA structure of an active gene, thereby blocking transcription
mRNA
(Thousands of copies)
Applications
The technology is applicable to any disease where selective silencing of a target gene will have therapeutic effect eg. oncology, dominant genetic diseases, viral/bacterial infections.
Protein
(Thousands of copies)
How 
functions
The innovations
Development of oligonucleotide gene-specific medicines
Identification time of 2/3 months for the candidate-drug molecule instead of the conventional 2/3 years
Greater medicine efficacy
Reduced or absent therapy toxicity
Potentially efficacious applications in all therapeutic areas
